Swiss Government Seeks New Powers to Combat Drug Shortages

Switzerland is facing a pharmaceutical emergency, and the Federal Council is finally stepping in to take charge. With hundreds of essential medicines currently missing from pharmacy shelves, the government has declared that the status quo is no longer sustainable. In a decisive move announced on Wednesday, federal authorities signaled their intent to strip supply management responsibilities from the cantons and the private sector during critical shortages.

For too long, the fragmented system has relied on local governance and market forces, a strategy that has crumbled under the weight of global supply chain disruptions. The government is now demanding the constitutional authority to intervene directly. This is not merely a bureaucratic adjustment; it is a fundamental power shift designed to centralize crisis management. By taking the reins, Bern aims to prevent the chaotic scrambling for resources that has plagued the healthcare system, ensuring that national security interests override cantonal borders when public health is on the line.

While the public outcry has birthed the "Yes to medical supply security" initiative, the Federal Council has boldly rejected the proposal as insufficient. Government officials argue that the popular initiative, which calls for the promotion of domestic research, development, and production, lacks the precision required to solve the immediate crisis. Instead of endorsing this broad mandate, the government is engineering a strategic counter-proposal.

This move highlights a sharp contrast in philosophy: while the initiative seeks long-term industrial independence, the government prioritizes immediate, targeted legal authority to manage existing stocks. The Federal Council explicitly stated that the popular initiative is "not effective or targeted enough" to guarantee the flow of goods now. By drafting a direct counter-proposal, Bern is attempting to sideline the initiative's broader economic goals in favor of a laser-focused constitutional amendment that grants them specific emergency powers without the baggage of a complete industrial overhaul.

The scale of the shortage is staggering. Hundreds of different medications are currently unavailable across the Swiss Confederation, leaving patients and doctors in a precarious position. The Federal Council has identified three critical pillars of the healthcare system that are most at risk: painkillers, vaccines, and antibiotics. These are not niche treatments; they are the bedrock of modern medicine, and their absence poses a direct threat to public safety.

"A good supply of medicines... is essential for the population," the Federal Council declared, underscoring the severity of the situation. The shortage is not a hypothetical future risk—it is a present reality where hospitals grapple with dwindling stocks of life-saving compounds. The new federal mandate aims to secure the basic supply of these specific categories, ensuring that even in the event of global disruptions, Switzerland retains a strategic reserve and a distribution mechanism that functions without delay.

The clock is ticking, and the government has set an aggressive timeline. A direct counter-proposal is to be drawn up by the summer of 2025, signaling an urgent need for legislative speed that is rare in Swiss politics. This deadline reflects the acute pressure on federal authorities to demonstrate action before the healthcare system faces another winter of discontent.

If successful, this constitutional amendment will fundamentally alter the relationship between the federal government and the healthcare sector. It represents a permanent shift toward centralization in times of crisis. As the summer approaches, all eyes will be on Bern to see if they can craft a legal framework that is robust enough to secure the nation's medicine cabinet while navigating the complex political landscape of direct democracy. The message is clear: the era of cantonal autonomy in drug security is coming to an abrupt end.